Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2012

View Archived Issues

Novel GlyT1 inhibitors developed

Canadian study assesses involvement of neuroinflammation in healthy aging humans

Agenus and GSK expand license agreement for vaccine adjuvant

FDA clears IND application for phase III trial of melanoma vaccine

Phase III SAR-1118 trial completes enrollment

Palatin Technologies completes enrollment in phase IIb bremelanotide trial

Bayer HealthCare obtains new product approval

Isis launches phase I trial of first-generation antisense drug

Novel candidate schizophrenia therapies patented by Takeda

RaQualia Pharma presents novel sodium channel antagonists

Roche develops new inhibitors of tyrosine-protein kinase BTK

Novel phosphodiesterase 9A inhibitors reported

Celgene completes acquisition

NeuroTherapeutics Pharma divulges new GABA(A) receptor antagonists

Researchers in U.S. design new therapeutics for radiation injury

Benitec Biopharma enters into new licensing agreement

University of Dundee and GSK to target neglected parasitic diseases

Apexigen grants license for APX-004 development in China

Viral Genetics submits pre-IND for Lyme disease treatment

Gene-modified stem cell therapy shows promise to combat HIV infection

Study of AEZS-130 in cancer cachexia begins

Thrombotech clear to test THR-18 in U.S.

Apogenix's phase II trial in glioblastoma multiforme meets primary endpoint

Repligen submits MAA for SecreFlo

Recombinant protein therapy active against HIV in phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...